OSE Immunotherapeutics and ARCAGY – GINECO Announce Initiation of a Randomized Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Pembrolizumab in Ovarian Cancer

NEXT STORY
Phase 3 trial of Libtayo® (cemiplimab) monotherapy in advanced cervical cancer stopped early for positive result on overall survival           
PREV STORY
CeraCare Reviews – Blood Sugar Supplement – Product Review by ProductWorld
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

FDA Approves Agile Therapeutics, Inc.’s Twirla® (levonorgestrel and ethinyl estradiol) Transdermal System – A New Weekly Contraceptive Patch Delivering a 30 mcg Daily Dose of Estrogen and 120 mcg Daily Dose of Progestin

author_avatar
NASDAQ Market News

Spero Therapeutics to Present New Preclinical Data for SPR994 at ASM Microbe 2018

Eighteen presentations with data across multiple pipeline candidates including data supporting SPR994’s broad spectrum ...

author_avatar
NASDAQ Market News

Asterias Biotherapeutics to Report Second Quarter 2018 Results on August 9, 2018

FREMONT, Calif., July 26, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a ...

author_avatar
NASDAQ Market News